记者 沈思怡 昨天，奉贤区举办2025贤商大会，近450名来自奉贤各行各业的企业家、商会代表在这场一年一度 的民营经济大会上齐聚一堂。现场，奉贤区对十大领航贤商、十大先锋贤商、十大青创贤商、优秀创新 创业案例等相关企业代表进行表彰。 奉贤是上海民营经济最活跃的区域之一。2024年，奉贤全区民营企业数量占企业总数近九成，贡献 了超六成规上工业产值、过半的税收以及超六成就业岗位。 这场大会上，既有在奉贤深耕多年、加码增资的"老朋友"，也有带着前沿技术与全球视野前来 的"新朋友"。他们的故事为解码奉贤民营经济的韧性与活力提供了鲜活样本。 生态引"新朋友"落子布局 耀速科技是一家专注于类器官芯片技术的公司，核心团队成员出自美国顶尖科研院所。2024年，团 队正式回国布局，将上海研发运营中心落子在奉贤临港南桥科技城。虽然企业成立时间不久，却已频频 受到行业巨头青睐。无论是跨国制药公司、国内头部药企，还是手握新药研发外包全球订单的CRO （合同研究组织）公司，都把合作的橄榄枝递向耀速的核心产品"器官芯片"。 通俗地说，器官芯片就是"在芯片上造器官"，它是一种含有活细胞和微流控芯片的生物工程装置， 可模拟真实器官的结构和功 ...

Core Viewpoint - The CDC has issued a directive to end all research projects involving the use of monkeys by the end of this year, marking a significant shift in animal research policy in the U.S. [3][4] Group 1: CDC Directive and Its Implications - The directive affects approximately 200 monkeys used primarily for infectious disease research, including HIV prevention and antiviral treatments [3]. - This is the first time a U.S. government agency has terminated non-human primate research since the NIH initiated a retirement plan for chimpanzees a decade ago [3]. - The future of these monkeys is uncertain, with possibilities including relocation to primate sanctuaries or euthanasia [3]. Group 2: New Methodologies in Research - Advocates for "new methodologies" such as organoids believe this marks the beginning of a "post-animal era" in research [3]. - The CDC's directive is seen as a potential model for transitioning to advanced alternative technologies, although achieving complete replacement of animal models is complex [4]. - The NIH still oversees nearly 7,000 non-human primates, indicating that the CDC's directive does not apply to all research institutions [4]. Group 3: Challenges of Replacement Technologies - Experts caution that while organoids and other new methodologies show promise, they cannot fully replicate the complexity of human diseases [4]. - The current state of recognized alternatives to animal testing remains limited, with few validated methods available [4]. - The debate continues on the extent to which organoids can replace animal models in biomedical research [4]. Group 4: Global Perspective and Future Directions - The focus should be on which countries can effectively implement alternative methodologies in translational medicine and drug evaluation [5]. - The CDC's decision highlights a growing contradiction in biomedical research: the need for new therapies while still relying on animal models for certain critical research areas [5]. - Addressing the balance between ethical considerations and scientific needs is essential for the advancement of both science and ethics [5].

Core Viewpoint - The CDC has issued a directive to end all research projects involving the use of monkeys by the end of this year, marking a significant shift in animal research policy in the U.S. [2] Group 1: Research and Policy Changes - Approximately 200 monkeys used for infectious disease research, including HIV and hepatitis, will be affected by the CDC's directive [2] - This is the first time a U.S. government agency has terminated non-human primate research projects since the NIH initiated a retirement plan for chimpanzees a decade ago [2] - The directive may lead to some monkeys being transferred to primate sanctuaries, while others may face euthanasia [2] Group 2: Alternative Research Methods - The announcement has sparked discussions among advocates of "new methodologies," suggesting a transition to a "post-animal era" in research [2] - The NIH still oversees nearly 7,000 non-human primates, indicating that the CDC's directive does not apply to all animal research in the U.S. [3] - Experts highlight that while the CDC's decision may be framed as a move towards advanced alternative technologies, fully replacing animal models is complex and not straightforward [3] Group 3: Global Perspective and Future Implications - The focus should be on which countries can develop solid results in alternative methodologies to gain a competitive edge in translational medicine and drug evaluation [4] - The termination of the monkey research program highlights a growing contradiction in biomedical research: the need for new therapies while determining when animal models are essential [4] - Responsible answers to the questions of when to use animals versus alternative methods are crucial for advancing both science and ethics [4]

Core Viewpoint - The 2025 Young Industrial Technology Innovation and Green Development Conference in Nanjing showcased advancements in light industry, emphasizing the shift from traditional manufacturing to intelligent manufacturing driven by technological innovation [1][3]. Group 1: Technological Innovations - Nanjing's light industry is transitioning towards intelligent manufacturing, with companies like Le Ying Technology adopting high-pressure instant sterilization technology for rice production, achieving sterilization in just 45 seconds [3][4]. - Le Ying Technology's automated rice production line can produce 12,000 boxes of rice per hour, totaling 200,000 servings daily, with only six employees required for operation, significantly reducing labor costs compared to traditional methods [5]. - The company reported a 13.83% year-on-year increase in export revenue, with six production lines exported to Japan alone [5]. Group 2: Industry Growth - The number of large-scale light industry enterprises in China increased from 108,700 in 2020 to 140,000 by October this year, with an average annual growth rate of 6.4% [10]. - The average annual revenue growth for these enterprises stands at 4.22% [10]. Group 3: Product Development and Precision - Le Hui International's digital factory in Nanjing achieves a filling accuracy of less than 0.5 grams for bottled beverages, utilizing advanced technology for precise control [6][7]. - The introduction of automated welding robots has reduced welding time by 50% and decreased defect rates by over 70%, enhancing product quality and efficiency [7][8]. Group 4: Biotech Innovations - Jiangsu Aiwei Biotechnology's organ-on-a-chip technology allows for the cultivation of human skin tissue in a controlled environment, facilitating cosmetic safety evaluations and drug testing [9][10]. - This technology offers a cost-effective and standardized solution for drug development and precision medicine [9].

Group 1 - QYResearch is recognized for its authoritative industry analysis and customized reports, widely cited by numerous well-known domestic and international companies, securities firms, and media [1] - The ASIC design service market in China is projected to generate sales revenue of $1.503 billion in 2023, with expectations to reach $3.416 billion by 2030 [2] - The global servo system market is estimated to be $15.611 billion in 2023, with a compound annual growth rate (CAGR) of 4.73%, reaching $20.604 billion by 2029 [5] Group 2 - The global vehicle dashboard market is dominated by a leading domestic company, ranked first in China and eighth globally, according to QYResearch [7] - The global humidifier market is expected to grow at a CAGR of over 10% in the next five years, with integrated and smart products taking a leading position [10] - The market for osmotic laxatives in China is projected to exceed 7.313 billion yuan by 2029, capturing 33.65% of the total constipation medication market [12] Group 3 - The global high-speed connector market is anticipated to reach $21.6 billion by 2030, providing significant expansion opportunities for suppliers [15] - The directional drilling tools market is expected to exceed $9.42 billion in 2024 and surpass $26.88 billion by 2037, with a CAGR of over 8.4% [17] - The global optical switch market is projected to reach $2.02 billion by 2031, with a CAGR of 16.3% [20] Group 4 - The global semiconductor robot market is currently dominated by foreign manufacturers, holding over 90% of the market share in China [22] - The global automatic wafer testing probe market is estimated to be around $1.156 billion in 2024, characterized by high market concentration [24] - The global emergency kit market is expected to reach $1.061 billion by 2031, with a CAGR of approximately 7.3% [27] Group 5 - The global home wireless router market is projected to grow at a CAGR of 5.8% from 2025 to 2031 [29] - The global medical device market is expected to reach $635.8 billion by 2024 [32] - The global SD-WAN market is estimated to reach $51.8 billion by 2031, with a CAGR of 32.6% [35] Group 6 - The global organ-on-a-chip market is expected to grow at a CAGR of 31.2% from 2024 to 2030 [69] - The global automotive drive motor core market is projected to reach $4.678 billion by 2030, with a CAGR of 11.85% [62] - The global eSIM card market is entering a rapid expansion phase, particularly in the IoT and consumer electronics sectors [65]

Core Insights - The "Invest Chengdu" Future Industry Investment Alliance held its first financing roadshow event, showcasing five high-quality companies from future industries with a total financing demand exceeding 700 million yuan [2][5] Group 1: Event Overview - The event took place on September 26 at the Chengdu Private Economy Development Promotion Center, focusing on future industries such as future energy, satellite communication, new displays, high-end equipment, and biotechnology [2][3] - The Chengdu government aims to strengthen the "Invest Chengdu" brand and establish a "tropical rainforest" fund ecosystem to support these industries [2] Group 2: Company Highlights - Chengdu Chenxian Optoelectronics Co., Ltd. presented its Micro-LED production line with a technology transfer yield of 99.995%, seeking 500 to 1,000 million yuan for production line construction and R&D [4] - Sichuan Rongxin New Energy Power System Co., Ltd. showcased its leading technology in high-power fuel cell hybrid systems, with applications in rail and road transportation [4] Group 3: Investment Engagement - Notable investment institutions such as Hillhouse Capital and Dongfang Fuhai participated, engaging in discussions on technology maturity, application scenarios, and market potential [5] - The event facilitated precise matching between investors and projects, with a total financing demand of over 700 million yuan reported [5] Group 4: Government Support and Future Plans - Chengdu's government has launched the "Tomorrow Star" initiative to support innovative companies with significant market potential and disruptive technologies [6] - The future industry fund aims to provide comprehensive capital services throughout the lifecycle of enterprises, focusing on seed, startup, and growth stages [10][11]

Core Concept - The emergence of organ-on-a-chip technology represents a significant advancement in biomedical research, offering a more accurate and ethical alternative to traditional animal testing methods [4][7]. Industry Overview - Organ chips are micro-engineered devices that simulate human organ functions using human cells, providing a platform for drug testing and disease modeling [2][3]. - The global organ-on-a-chip market is projected to grow at a compound annual growth rate (CAGR) of 31.2% from 2024 to 2030, indicating strong market potential [8]. Technological Advancements - Organ chips utilize microfluidic technology to create a controlled environment for cell growth, mimicking the physiological conditions of human organs [2][3]. - High-throughput organ chips can conduct thousands of tests simultaneously, significantly reducing the time and resources needed for drug development [5][6]. Advantages Over Traditional Methods - Organ chips can provide more accurate predictions of human responses to drugs compared to animal models, with studies showing accuracy improvements of 7 to 8 times in predicting drug-induced liver damage [4]. - The cost of using organ chips for drug testing is only 10% to 20% of that of traditional animal models, making it a cost-effective solution for pharmaceutical companies [7]. Applications in Drug Development - Organ chips can be used to test the efficacy and safety of drugs on patient-specific cells, allowing for personalized medicine approaches without risking patient health [7]. - The technology serves as a complementary tool to existing drug development processes, potentially shortening the research timeline and reducing costs [7].

Core Concept - Organ chips represent a significant advancement in biomedical research, utilizing human cells to create miniaturized organ models for drug testing and disease research, offering a more accurate alternative to traditional animal models [4][6][7]. Group 1: Technology Overview - Organ chips are built on a foundation of microfluidic technology, integrating human cells and biological materials to simulate organ functions and responses [2][3]. - The first fully functional organ chip, the "lung chip," was developed around 2009, and research in this field has been ongoing for over a decade in China [3][5]. - These chips can replicate complex physiological environments, allowing for precise drug testing and disease modeling [3][6]. Group 2: Advantages Over Traditional Methods - Organ chips significantly reduce the reliance on animal testing, addressing ethical concerns and providing more relevant data for human biology [4][6]. - They offer a high-throughput capability, enabling extensive data analysis and reducing the time required for drug testing from 90-180 days to just 6 days for 100 compounds [6][7]. - The cost of using organ chips is only 10% to 20% of traditional animal models, making them a cost-effective solution for drug development [7]. Group 3: Market Potential - The global organ chip market is projected to grow at a compound annual growth rate (CAGR) of 31.2% from 2024 to 2030, indicating strong future demand for this technology [8]. Group 4: Challenges Ahead - Despite the promising potential of organ chips, the transition from scientific research to practical application faces challenges that need to be addressed [9].

Group 1 - The People's Bank of China and seven other departments have introduced 18 financial measures to enhance financial support for new industrialization [1] - Financial institutions are integrating "bank counters" into laboratories and connecting "industrial chains" with "capital chains" to create a multi-dimensional ecosystem for financial empowerment [1] - The organ-on-a-chip technology is highlighted as a cutting-edge technology in biomedicine, but funding shortages pose significant challenges for commercialization [1] Group 2 - The "Achievement Transformation Loan" has been innovatively launched by the Jiangsu branch of the People's Bank of China to support research teams [2] - A research team received a credit support of 10 million yuan within two weeks, significantly accelerating the development process of the organ-on-a-chip project [3] Group 3 - In Zhejiang, financial institutions are providing funding support for enterprises undergoing transformation and upgrading through innovative financial products [4] - A high-tech enterprise in Wenzhou received a loan of 130 million yuan to introduce advanced production lines, increasing capacity by 30% [7] Group 4 - The scale of technology loans in Zhejiang has exceeded 4 trillion yuan, with a growth rate of over 15% [8] - Financial institutions are breaking traditional credit restrictions to support green and low-carbon transformations in traditional manufacturing [10] - A company in the aluminum industry received over 100 million yuan in funding support for its green transformation projects, aiming for a 10% reduction in carbon emissions by the end of the year [10]

Group 1 - The "Longzi Lake Sci-tech Roadshow" event showcased 220 technological achievements, 34 quality projects, and 17 key cooperation projects signed on-site, aimed at accelerating the transformation of scientific research results from "shelf to market" [1] - The event highlighted innovations in various fields such as new generation information technology, high-end equipment, intelligent perception, and green industries, with representatives from investment institutions and enterprises seeking collaboration opportunities immediately after project presentations [1] - The event facilitated a platform for scientists and industry to connect, allowing precise identification of industrial needs and accelerating the application of research outcomes [2] Group 2 - The signing of contracts during the event reached several million yuan, with projects including semiconductor equipment and agricultural equipment being showcased [2] - The launch of a large instrument and equipment sharing platform by the Henan Academy of Sciences aims to eliminate the issues of scattered and idle instruments, making research equipment a public utility for innovation across the province [2] - The "Longzi Lake Sci-tech Roadshow" series has been actively promoting the transformation of scientific achievements and nurturing new productive forces since its inception in 2025, with a focus on various fields including traditional Chinese medicine, building materials, quantum technology, and new materials [2][3] Group 3 - The event aims to deepen the integration of technological innovation and industrial innovation, facilitating the rapid transformation of scientific achievements into new productive forces [3] - The Henan Academy of Sciences plans to hold two specialized events each month, focusing on key areas and weak links in the province's industrial chain, to support the construction of a modern industrial system in Henan [3]